What are the Historical Developments and Current Growth Metrics of the Prenatal And Newborn Genetic Testing Market?
The prenatal and newborn genetic testing market has seen considerable growth due to a variety of factors.
• In the past few years, there has been a significant expansion in the prenatal and newborn genetic testing market size. Projected to rise from $6.68 billion in 2024 to $7.61 billion in 2025, it suggests a compound annual growth rate (CAGR) of 13.9%.
The surge during the past period is credited to enhancements in non-invasive prenatal testing, a rise in maternal age, governmental assistance and health policies, as well as the patient's desire for early detection.
What Does Future Hold for The Prenatal And Newborn Genetic Testing Market By 2029?
The prenatal and newborn genetic testing market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the prenatal and newborn genetic testing market is predicted to experience swift expansion. The market size is forecasted to reach $12.04 billion by 2029 with a compound annual growth rate (CAGR) of 12.1%.
The projection for this growth is due to factors such as the broadening of genetic test panels, increased awareness about maternal health, guidelines for prenatal and newborn screening, heightened attention towards rare diseases and considerations concerning regulations and ethics. Key trends to watch during this forecast period would be non-invasive prenatal testing (NIPT), whole exome and genome sequencing, the incorporation of artificial intelligence (AI), preimplantation genetic testing (PGT), and genetic testing that is directly available to consumers.
What Are The Primary Growth Drivers In The Prenatal And Newborn Genetic Testing Market?
The prenatal and newborn genetic testing markets are predicted to grow, spurred by government initiatives and backing for such testing. These initiatives incorporate specific actions or policies taken on by the government at either local, regional, or national scale in order to address specific issues or improve citizens' welfare. These initiatives, specifically targeted at prenatal and newborn genetic testing, aid the population by facilitating identification of genetic abnormalities in fetuses during pregnancy or newborns soon after birth. An instance of this occurred in June 2022 when the Australian government pledged an annual provision of $1.3 million to the New South Wales newborn screening programme, which allowed all newborns in the state free access to tests for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA) among other genetic newborn screenings. These screenings, projected to be provided to approximately 100,000 newborns annually, would potentially save up to 13 of these newborns afflicted with these genetic disorders. Consequently, these governmental initiatives and support drive the growth of the prenatal and newborn genetic testing markets. The prospect of the prenatal and newborn genetic testing market is further boosted by the rising prevalent cases of genetic disorders. These medical conditions occur due to abnormalities or mutation in a person's DNA or genetic material. Identifications of these genetic disorders can be made early through prenatal and newborn genetic testing, enabling healthcare providers to implement interventions and treatment strategies in a timely manner. For example, the Centers for Disease Control and Prevention (CDC), a public health agency based in the US, revealed in May 2024 that about 100,000 US residents suffer from sickle cell disease (SCD). Majority of these affected individuals are non-Hispanic Black or African American while an estimated 3%-9% are Hispanic or Latino. This surge in the occurrence of genetic disorders is therefore significantly propelling the growth of the prenatal and newborn genetic testing market.
What Is The Segmentation Of The Global Prenatal And Newborn Genetic Testing Market?
The prenatal and newborn genetic testing market covered in this report is segmented –
1) By Product Type: Consumables, Instruments
2) By Screening: Non-Invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Other Screenings
3) By Disease: Down Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anemia
4) By End User: Hospital, Maternity And Specialty Clinics, Diagnostic Centers
Subsegments:
1) By Consumables: Reagents And Assays, Sample Collection Kits, Test Kits
2) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Analyzers
Pre-Book The Prenatal And Newborn Genetic Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Prenatal And Newborn Genetic Testing Market?
Leading firms in the prenatal and newborn genetic testing sectors are concentrating on the creation of innovative screening exams, such as non-invasive prenatal screening tests, intending to make them more affordable and accessible, thereby enhancing their reliability. Noninvasive prenatal screening (NIPS), also known as noninvasive prenatal testing (NIPT), is a sophisticated, secure method for genetic screening during pregnancy, which helps determine the likelihood of specific chromosomal irregularities in the fetus. For example, Juno Diagnostics Inc., an American healthcare technology firm, unveiled Juno Hazel in November 2022. This noninvasive prenatal screening test identifies chromosomal abnormalities and delivers clinical content. The implementation of a sample collection kit removes the need for phlebotomy, enhancing the test's accessibility. The company aims to provide educational materials and tailored genetic counseling support by collaborating with physicians and genetic counselors.
Who Are the Key Players In The Prenatal And Newborn Genetic Testing Market?
Major companies operating in the prenatal and newborn genetic testing market report are:
• F. Hoffmann-La Roche AG
• Novartis AG
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Siemens Healthineers AG
• Becton
• Dickinson and Company
• Quest Diagnostic Incorporated
• Agilent Technologies Inc.
• Grifols S.A.
• Terumo Corporation
• Illumina Inc.
• PerkinElmer Genomics
• Quidel Corporation
• Bio-Rad Laboratories Inc.
• Qiagen NV
• Werfen S.A.
• DiaSorin S.p.A
• Nova Biomedical
• BGI Group
• Natera Inc.
• Trinity Biotech PLC
• Meridian Bioscience Inc.
• Sekisui Diagnostics
• Chembio Diagnostics
• PTS Diagnostics
• Ariosa Diagnostics Inc.
• AccuBioTech Co. Ltd.
• Sequenom Inc.
What Are The Regional Insights Into The Prenatal And Newborn Genetic Testing Market?
North America was the largest region in the prenatal and newborn genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prenatal and newborn genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
